Author:
Grimm Sabine Elisabeth,Strong Mark,Brennan Alan,Wailoo Allan J.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference29 articles.
1. European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004. London: EMA; 2016.
2. European Medicines Agency. Adaptive Pathways 2014.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000601.jsp
. Accessed 21 Aug 2017.
3. Garrison LP Jr, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703–19.
4. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value Health. 2012;15(3):570–9.
5. Rothery C, Claxton K, Palmer S, Epstein D, Tarricone R, Sculpher M. Characterising uncertainty in the assessment of medical devices and determining future research needs. Health Econ. 2017;26(Suppl 1):109–23.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献